

1 **Frequency of antimicrobial-resistant bloodstream infections in Thailand, 2022**

2

3 **Running Title: AMR BSI in Thailand, 2022**

4

5 Krittiya Tuamsuwan, Panida Chamawan, Phairam Boonyarit, Voranadda Srisuphan, Preeyarach
6 Klaytong, Chalida Rangsiwutisak, Prapass Wannapinij, Trithep Fongthong, John Stelling, Paul
7 Turner, Direk Limmathurotsakul.

8

9 The Office of Permanent Secretary, Ministry of Public Health, Nonthaburi, 11000, Thailand
10 (K.T., P.C., P.B., V.S., T.F.)

11 Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol
12 University, Bangkok, Thailand (P.K., C.R., P.W., D.L.)

13 Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States (JS)
14 Cambodia-Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap, Cambodia
15 (PT)

16 Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
17 Oxford, Oxford, United Kingdom (P.T., D.L.)

18 Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok,
19 Thailand (D.L.)

20

21 **Corresponding author:** Prof. Direk Limmathurotsakul, Mahidol-Oxford Tropical Medicine
22 Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok,
23 10400, Thailand. Tel: +66 2 203 6333, Fax: +66 2 354 9169, e-mail: direk@tropmedres.ac

24

25 **Word count:** Abstract 200; Text 3,735; Tables 4; Figures 2

26

27 **Key words:** Antimicrobial resistant, surveillance, bloodstream infection, proportion, incidence,
28 frequency

29

30 **Declaration of interest:** none

31

32 **ORCID**

33 Preeyarach Klaytong 0000-0002-9906-5159

34 Chalida Rangsiwutisak 0009-0007-9380-9085

35 Paul Turner 0000-0002-1013-7815

36 Direk Limmathurotsakul 0000-0001-7240-5320

37

38 **Highlights**

- 39
- The frequency of AMR BSI in 111 public hospitals in Thailand in 2022 was studied.
- 40
- The frequency of community-origin 3GCREC BSI was different by regions.
- 41
- The frequency of hospital-origin CRAB BSI varied greatly among hospitals.
- 42
- Underuse of BC was associated with the higher frequency of AMR BSI per tested
- 43 patients.
- 44
- Our findings contributed to actions against AMR at local and national levels.

45

46 **Abstract**

47 **Objectives**

48 To evaluate the frequency of antimicrobial-resistant bloodstream infections (AMR BSI) in
49 Thailand

50

51 **Methods**

52 We analyzed data from 2022, generated by 111 public hospitals in health regions 1 to 12, using
53 the AutoMated tool for Antimicrobial resistance Surveillance System (AMASS) and submitted to
54 the Ministry of Public Health, Thailand. Multilevel Poisson regression models were used.

55

56 **Results**

57 The most common cause of community-origin AMR BSI was third-generation cephalosporin-
58 resistant *Escherichia coli* (3GCREC, 65.6%; 5,101/7,773 patients) and of hospital-origin AMR
59 BSI was carbapenem-resistant *Acinetobacter baumannii* (CRAB, 51.2%, 4,968/9,747 patients).

60 The percentage of patients tested for BSI was negatively associated with the frequency of
61 community-origin 3GCREC BSI and hospital-origin CRAB BSI. Hospitals in health regions 4
62 (lower central) had the highest frequency of community-origin 3GCREC BSI per 100,000 tested
63 patients (adjusted incidence rate ratio, 2.06; 95% confidence interval: 1.52-2.97). Health regions
64 were not associated with the frequency of hospital-origin CRAB BSI, although between-hospital
65 variation was high even adjusting for hospital level and size.

66

67 **Conclusion**

68 The high between-hospital variation of hospital-origin CRAB BSI suggests the importance of
69 hospital-specific factors. Our approach and findings highlight health regions and hospitals where
70 actions against AMR infection, including antimicrobial stewardship and infection control, should
71 be prioritized.

72

73 **Introduction**

74 Strengthening the knowledge and evidence base through surveillance and research is one of
75 the five key objectives outlined in the global action plan on antimicrobial resistance (AMR), led
76 by the World Health Organization (WHO) [1]. At the global level, the WHO Global Antimicrobial
77 Resistance and Use Surveillance System (GLASS) has provided a standard approach to the
78 collection, analysis and sharing of data [2]. The GLASS country profile dashboard presents
79 summaries of AMR data (including AMR proportions and AMR frequency) that each country
80 reported to the system [3]. In addition, many high-income countries (HICs), such as England,
81 have collated and made local AMR data available via a publicly accessible web tool [4]. Better
82 access, use and research on surveillance data have been one of the main elements to tackle
83 AMR [4-6].

84

85 In 2020, we developed the AutoMated tool for Antimicrobial resistance Surveillance System
86 (AMASS), an offline application that allow hospitals to automatically analyse and generate
87 standardized antimicrobial resistance (AMR) surveillance reports from their routine microbiology
88 and hospital data [7]. This tool was designed to overcome the limitations of inadequate human
89 resources to analyze AMR data and generate summary reports in low and middle-income
90 countries (LMICs). The automatically generated reports stratify infection origin into community-
91 origin and hospital-origin based on the recommendations of WHO GLASS [2] and provide
92 additional reports on mortality (%) and total number of deaths following AMR and non-AMR
93 bloodstream infections (BSI). We initially tested the application in seven hospitals in seven
94 countries [7]. We recently reported the difference of frequency of hospital-origin AMR BSI
95 between tertiary-care hospitals (TCHs) and secondary-care hospitals (SCHs) using the AMASS
96 and a retrospective data in 49 public hospitals from 2012 to 2015 [8]. From December 2022 to
97 January 2023, on behalf of the Health Administration Division, Ministry of Public Health (MoPH)

98 Thailand, we trained 25 public hospitals in Thailand to utilize the AMASS, and reported the
99 benefit of local and timely AMR data review [9].

100
101 Following the success of the early implementation of the AMASS in 25 public hospitals [9], in
102 2023 the MoPH invited all 127 public referral hospitals in Thailand to utilize the AMASS using
103 their data from 2022 and submit the summary data to the MoPH. This study aims to evaluate
104 the frequency of community-origin and hospital-origin AMR BSI in Thailand.

105

106 **Materials and Methods**

107 **Study setting**

108 In 2022, Thailand had a population of 66.1 million, consisted of 77 provinces, and covered
109 513,120 km². The health systems in each province were integrated into 12 groups of provinces,
110 known as health regions, plus the capital Bangkok as health region 13 (Figure 1A), using the
111 concept of decentralization [10]. The Health Administration Division, Ministry of Public Health
112 (MoPH) supervised 127 public referral hospitals in health regions 1 to 12. These included 35
113 advanced-level referral hospital (i.e. level A, with a bed size of about 500-1,200), 55 standard-
114 level referral hospital (i.e. level S, with a bed size of about 300-500) and 37 mid-level referral
115 hospital (i.e. level M1, with a bed size of about 180-300) [11]. All level A and S hospitals, and
116 most of level M1 hospitals were equipped with a microbiology laboratory capable of performing
117 bacterial culture using standard methodologies for bacterial identification and susceptibility
118 testing provided by the Department of Medical Sciences, MoPH.

119

120 **Study tool and its implementation**

121 From 16 December 2022 to 30 June 2023, on behalf of the Health Administration Division,
122 MoPH, we invited and trained staff from 127 public referral hospitals in health regions 1 to 12 to
123 utilize the AMASS with their own microbiology and hospital admission data files via four online

124 meetings, five face-to-face meetings and on-line support. Then, the MoPH invited all 127 public
125 referral hospitals to utilize the AMASS in 2023 using their data from 2022. The additional two
126 online meetings for 127 hospitals were conducted in January 2023, and the four face-to-face
127 meetings were conducted in Chonburi (for hospitals in health regions 4, 5 and 6), Chiang Mai
128 (for hospitals in health regions 1, 2 and 3), Surajthani (for hospitals in health regions 11 and 12)
129 and Khon Kaen (for hospital in health regions 7, 8, 9 and 10) provinces in January and February
130 2023.

131
132 The content of the online meetings and face-to-face meetings were as previously described [9].
133 In short, we taught the hospitals how to use the AMASS, complete the data dictionary files, and
134 verify and read the AMR reports automatically generated by the AMASS. The hospitals were
135 request to validate the reports using two methods: (a) checking data verification log files
136 generated the AMASS whether all information was imported accurately (e.g. total number of
137 specimens, total number of hospital admissions, number of missing values, total number of
138 isolates per organism in the raw microbiology data file, total number of antibiotics being tested,
139 and all pathogens and antimicrobial susceptibility testing results under evaluation), and (b)
140 comparing the summary data and reported generated by the AMASS with data generated from
141 manual calculations obtained from complete line listing of several organisms. The hospitals
142 were asked to re-export the data files (if needed), complete the data dictionary files, re-run the
143 AMASS and verify the reports until the reports were accurate. The 25 hospitals who were
144 initially trained in the first round [9] supported the other hospitals in their health regions.

145
146 Then, the hospitals who completed the utilization of the AMASS submitted the summary data
147 generated by the AMASS to the MoPH. A new interactive Thailand AMR dashboard was
148 launched in 2023 and is open-access (Figure 2) [12].

149

150 **Study design**

151 This is a retrospective study evaluating frequency of AMR BSI across public referral hospitals in
152 Thailand using the hospital-level AMR data submitted to the MoPH. For AMR infections, we
153 initially analyzed the following organisms: carbapenem-resistant *Acinetobacter baumannii*
154 (CRAB), carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), carbapenem-resistant
155 *Escherichia coli* (CREC), carbapenem-resistant *Klebsiella pneumoniae* (CRKP), third-
156 generation cephalosporin-resistant *E. coli* (3GCREC) and *K. pneumoniae* (3GCRKP), and
157 methicillin-resistant *Staphylococcus aureus* (MRSA) which are in the WHO GLASS priority list of
158 AMR bacteria and are of locally importance. Only blood culture (BC) results were included in the
159 analysis of the AMASS and in this study. The AMASS de-duplicated the data by selecting only
160 the first admission of a patient with BSI caused by a given bacterial species per patient per
161 reporting period and per infection origin.

162

163 **Definitions**

164 Community-origin BSI was defined for patients with first positive blood specimens in the hospital
165 taken within the first two calendar days of admission with calendar day one equal to the day of
166 admission [13]. Patients with first positive blood specimens taken after the first two calendar
167 days were categorized as cases of hospital-origin BSI. The classification of community-origin
168 and hospital-origin BSI was performed within the AMASS and based on specimen collection
169 dates and hospital admission dates extracted from the microbiology and hospital data files of
170 each hospital. Blood specimens collected from patients who were not admitted at the study
171 hospitals were excluded from the analysis. These specimens were categorized as BSI of
172 unknown origin in the summary reported generated by the AMASS [7].

173

174 Patients who had the first BC taken within the first two calendar days of hospital admission were
175 considered as having tested for community-origin BSI. Patients were considered at risk for

176 hospital-origin BSI after they stayed in the hospital for more than two calendar days. Patients
177 who had the first BC taken after the first two calendar days of hospital admission were
178 considered as having tested for hospital-origin BSI.

179
180 The proportion of AMR (%) was calculated as the percentage of patients with new AMR BSI
181 over all patients with new BSIs for each pathogen during the reporting period. The frequency of
182 AMR BSI for each pathogen was calculated as the total number of new patients with AMR BSI
183 during the reporting period per 100,000 tested patients, per 100,000 admissions and per
184 100,000 patient-days at risk for hospital-origin BSI.

185
186 Mortality (%) following AMR BSI for each pathogen under evaluation was calculated as the
187 percentage of patients with new AMR BSI who died in the hospital, using all-cause in-hospital
188 mortality in the discharge summary regularly completed by the attending physicians and
189 available in the admission data of the hospitals.

190

191 **Statistical analysis**

192 Medians, interquartile ranges (IQR) and ranges of continuous variables were estimated. IQRs
193 are presented in terms of 25th and 75th percentiles. For percentages, one digit after the decimal
194 points is shown when the total number of denominators is higher than 100. To evaluate BC
195 utilization, we calculated percentage of patients tested for BSI and rate of patients tested for BSI
196 per 1,000 bed-days. We did not calculate the total number of BC specimens per 1,000 bed-days
197 [14, 15], because, during the workshops, we observed that some hospitals recorded two BC
198 specimens as two separate records, while some hospitals recorded those as a single record in
199 their laboratory information systems (LIS). Therefore, we utilized the deduplicated number of
200 patients tested for BSI as the indicator of BC utilization. Kruskal Wallis test was used to
201 compare the median of continuous variables between groups.

202

203 We evaluated factors associated with the frequency of community-origin 3GCREC BSI and
204 hospital-origin CRAB BSI using univariable and multivariable Poisson random-effects regression
205 models. The community-origin 3GCREC BSI and hospital-origin CRAB BSI were selected as
206 they were the most common causes of community-origin and hospital-origin AMR BSI,
207 respectively. The random effect model accounts for the fact that the observed outcomes for
208 some hospitals can take on extreme values because of random variation. Factors evaluated
209 included health region, hospital level, hospital bed size, Gross Provincial Product (GPP), rate of
210 patients having BC taken per 1,000 patient-days, percentage of patients having BC taken within
211 the first two calendar days of hospital admission (for community-origin AMR BSI) and
212 percentage of patients having BC taken after first two calendar days of hospital admission (for
213 hospital-origin AMR BSI). Data of GPP of Thailand in 2021 was used as a proxy for the size of
214 the economy in each province [16]. We summarized results with incidence rate ratio (IRRs) and
215 95% confidence intervals (Cis).

216

217 To measure heterogeneity in the multilevel Poisson regression, we calculated the median rate
218 ratio (MRR) and variance partition coefficient (VPC) using the methods described by Austin et al
219 [17] (Appendix A). The MRR is the median relative change in the rate of the occurrence of the
220 event when comparing two hospitals (i.e. two clusters) with identical covariates from two
221 randomly selected different hospitals. The VPC denotes the proportion of the (unexplained)
222 variation in the outcome that is beyond that explained by the fixed effects of the covariates in
223 the models. In other words, the VPC denotes the proportion of the variation that is due to
224 between-hospital (i.e. between-cluster) variation [17]. We calculated the VPC using exact
225 calculations [17] and total number of tested patients for 111 covariate patterns of the 111
226 hospitals included in the study. We used STATA (version 14.2; College Station, Texas) for all
227 analyses.

228

229 **Data availability**

230 The hospital-level summary data used for the study are open-access and available at
231 <https://figshare.com/s/6aee792c15290d7dea3c>.

232

233 **Ethics**

234 Ethical permission for this study was obtained from the Institute for the Committee of the Faculty
235 of Tropical Medicine, Mahidol University (TMEC 23-085). Individual patient consent was not
236 sought as this was a retrospective study using summary data, and the Ethical and Scientific
237 Review Committees approved the process.

238

239

240 **Results**

241 **Baseline characteristics**

242 Of 127 public referral hospitals, 116 (91%) used the AMASS to analyze their microbiology and
243 hospital admission data files, and submitted the summary AMR surveillance reports and data
244 from 2022 to the MoPH. Four hospitals had no data of BC with 'no growth' results in the
245 electronic data file, and one hospital exported and used inaccurate hospital admission data.
246 These hospitals were removed from the analysis because the data of 'no growth' specimens
247 and accurate data of hospital admissions were required for calculating the frequency of AMR
248 BSI. Therefore, a total of 111 hospitals were included in the final analysis.

249

250 Of all public referral hospitals in Thailand, 100% of Level A hospitals (35/35), followed by 89% of
251 Level S hospitals (49/55) and 73% of Level M1 hospitals (27/37) were included in this study.
252 The data were available from 74 of 77 provinces (96%) in Thailand, all provinces except Mae
253 Hong Son, Nakorn Nayok and Bangkok.

254

255 From 1 January to 31 December 2022, there were 3,916,766 hospital admissions of 3,042,979
256 patients, totaling 23,675,466 patient-days, across 111 public referral hospitals included in the
257 study. Hospital characteristics are presented in Table 1 and S1. A total of 618,187 patients had
258 BC taken, resulting in 20.3% of patients having BC taken (618,187/3,024,360). Rate of patients
259 having BC taken was 26.1 per 1,000 patient-days (618,187/23,541,908).

260

261 The median percentage of patients having BC taken within the first two calendar days of
262 hospital admission was highest in Level A hospitals (18.8%), followed by that in Level S (16.5%)
263 and Level M1 (15.0%) hospitals ($p=0.11$). The median percentage of patients having the first BC
264 taken after the first two calendar days of hospital admission was also highest in Level A
265 hospitals (4.2%), followed by that in Level S (3.3%) and Level M1 (2.6%) hospitals ($p<0.001$).

266

267 **Total No. of cases and deaths following AMR BSI**

268 There were 7,829 patients with community-origin AMR BSI caused by the pathogens under
269 evaluation (Table 2). The most common cause of community-origin AMR BSI was 3GCREC,
270 accounting 65.9% (5,157/7,829) of those patients. The total number of deaths following
271 community-origin 3GCREC BSI was 1,048, representing 54.1% (1,048/1,936) of all deaths
272 following community-origin AMR BSI caused by pathogens under evaluation.

273

274 There were 9,567 patients with hospital-origin AMR BSI caused by the pathogens under
275 evaluation. The most common cause of hospital-AMR BSI was CRAB, accounting 51.3%
276 (4,926/9,602) of those patients. The total number of deaths following hospital-origin CRAB BSI
277 was 2,955, representing 58.7% (2,955/5,036) of all deaths following hospital-origin AMR BSI
278 caused by pathogens under evaluation.

279

280 **Factors associated with the frequency of community-origin 3GCREC BSI**

281 The median observed frequency of community-origin 3GCREC BSI per 100,000 patients tested
282 for community-origin BSI was 961 in Level A hospitals, 1,008 in Level S hospitals and 911 in
283 Level M1 hospitals. In the multivariable regression model (Table 3), hospital level and bed size
284 were not associated with the frequency of community-origin 3GCREC BSI ($p=0.50$ and 0.14 ,
285 respectively). Hospital region was independently associated with the frequency ($p<0.001$).
286 Hospitals in health regions 4 and 12 were associated the highest and lowest frequency,
287 respectively, and the adjusted incidence rate ratio (aIRR) was about double (aIRR, 2.07; 95%
288 confidence interval [CI] 1.53-2.80; Figure 1B). Rate of patients having BC taken per 1,000
289 patient-days was not included in the final model because of collinearity with the other variable
290 for BC utilization. Percentage of patients having BC taken within the first two calendar days of
291 hospital admission was negatively associated with the frequency of community-origin 3GCREC
292 BSI (aIRR 0.88, 95%CI 0.82-0.94, per 5 percentage point change, $p<0.001$).

293
294 There was between-hospital variation in the frequency of community-origin 3GCREC BSI in the
295 final multivariable regression model (the estimated variance of the distribution of the random
296 effects= 0.066 , $p<0.001$). The MRR was 1.28, representing the magnitude of between-hospital
297 variation in the frequency of community-origin 3GCREC BSI. The median VPC was 0.71 (Figure
298 S1 and S2), suggesting that, on average, 71% of the variation in the number of patients with
299 community-origin 3GCREC BSI was due to differences between hospitals, while the remaining
300 29% was based on factors included in the final multivariable models.

301
302 Similar findings were also observed for the frequency of community-origin 3GCREC BSI per
303 100,000 admissions (Table S2), except that percentage of patients having BC taken within the
304 first two calendar days of hospital admission was positively associated with the frequency of

305 community-origin 3GCREC BSI per 100,000 admissions (aIRR 1.20, 95%CI 1.12-0.30, per 5
306 percentage point change, $p < 0.001$).

307

308 **Factors associated with the frequency of hospital-origin CRAB BSI**

309 The median observed frequency of hospital-origin CRAB BSI per 100,000 patients tested for
310 hospital-origin BSI was 4,768 in Level A hospitals, 3,185 in Level S hospitals and 1,537 in Level
311 M1 hospitals. In the multivariable regression model (Table 4), hospital level and bed size were
312 independently associated with the frequency of hospital-origin CRAB BSI ($p = 0.010$ and 0.001 ,
313 respectively). Hospital region was not strongly associated with the frequency of hospital-origin
314 CRAB BSI ($p = 0.096$). The percentage of patients having BC taken after the first two calendar
315 days of hospital admission was negatively associated with the frequency of hospital-origin
316 CRAB BSI (aIRR 0.91, 95%CI 0.82-1.00, per 1 percentage point change, $p = 0.060$).

317

318 There was between-hospital variation in the frequency of hospital-origin CRAB BSI in the final
319 multivariable regression model (the estimated variance of the distribution of the random
320 effects = 0.184, $p < 0.001$). The MRR was 1.51, representing the magnitude of between-hospital
321 variation in the frequency of hospital-origin CRAB. The median VPC was 0.84 (Figure S3),
322 suggesting that on average 84% of the variation in the number of patients with hospital-origin
323 CRAB BSI was due to differences between hospitals. Figure S4 shows the differences in the
324 frequency of hospital-origin CRAB BSI of each hospital within the same hospital level.

325

326 Similar findings were also observed for frequency of hospital-origin CRAB BSI per 100,000
327 admissions and per 100,000 patient-days at risk, except that percentage of patients having BC
328 taken after the first two calendar days of hospital admission was positively associated with the
329 frequency of hospital-origin CRAB BSI per 100,000 admissions (aIRR 1.15, 95%CI: 1.04-1.28,

330 p=0.009, Table S3) and per 100,000 patient-days at risk of hospital-origin BSI (aIRR 1.09,
331 95%CI 0.99-1.20, p=0.092, respectively, Table S4).

332

333

334 **Discussion**

335 This study demonstrates the regional differences in frequency of community-origin 3GCREC
336 BSI in Thailand in 2022 after adjustment for the difference in hospital level, hospital bed size
337 and rate of patients having BC taken. Our study highlights the high variation of the frequency of
338 hospital-origin CRAB BSI between hospitals, suggesting that unadjusted factors at the hospital
339 level (e.g. differences in case-mix, and infection prevention control (IPC) and antimicrobial
340 stewardship (AMS) activities) are important.

341

342 Some health regions (e.g. 4, 5 and 7; Figure 1B) had relatively higher frequency of community-
343 origin 3GCREC BSI than the others. Lack of association between hospital level and the
344 frequency of community-origin 3GCREC BSI is consistent with the previous finding [8]. Our
345 study did not observe an association between the local economy (as measured by GPP) and
346 the frequency of community-origin 3GCREC BSI. Previous studies reported that regions, sex,
347 age and underlying diseases are associated with the incidence rate of AMR *E. coli* BSI [18, 19].
348 Further studies are needed to evaluate whether these factors (using patient-level data) and
349 other factors (e.g. antibiotic consumption at the provincial-level or regional-level) are associated
350 with the frequency of community-origin 3GCREC BSI. Those insights would be crucial for
351 formulating targeted interventions against community-acquired AMR infections in the country.

352

353 Association between hospital level and bed size and the frequency of hospital-origin CRAB BSI
354 is consistent with the previous findings [8, 20]. This is likely because large referral hospitals tend
355 to have a higher proportion of patients with severe conditions, or requiring complex surgery,

356 prolonged intubation or urinary catheters, and a higher proportion of intensive care beds.
357 Further studies are needed to evaluate and adjust for these factors using patient-level data. The
358 substantial between-hospital variation for hospital-origin CRAB BSI may also be due to the
359 differences in effectiveness of IPC and AMS activities implemented in each hospital. Due to the
360 inability to adjust for differences in case-mix, we cannot conclusively determine whether
361 hospitals with the highest frequency of hospital-origin CRAB BSI had less-effective IPC or AMS
362 activities. However, the MoPH is promptly prioritizing these hospitals for immediate actions,
363 including re-evaluation and reinforcement of IPC and AMS activities.

364

365 In line with previous studies [21, 22], our study shows that the under-utilization of BC could lead
366 to higher observed frequency of AMR BSI per 100,000 tested patients and the lower observed
367 frequency of AMR BSI per 100,000 admissions and per 100,000 patient-days. Possibly,
368 hospitals which under-utilize BC tend to perform BC sampling primarily among patients with
369 very severe infections or failure of empirical treatment. This would lead to a selection bias for
370 culture positivity for AMR pathogens (resulting in a higher frequency of AMR BSI per 100,000
371 tested patients being observed) and to misdiagnoses of AMR BSI in patients without BC taken
372 (resulting in a lower frequency per 100,000 admissions and per 100,000 patient-days being
373 observed) [21].

374

375 Our study has multiple strengths. First, the number of hospitals included in the analysis was
376 large. We also included a wide range of hospital levels and size. Second, we calculated and
377 adjusted for BC utilization in the multivariable models. Third, we systematically estimated the
378 magnitude of between-cluster variation [17, 23].

379

380 However, our study also has several limitations. First, we utilized summary data. Individual-level
381 data such as sex, age and underlying diseases were not available for analysis. Using individual-

382 level data and adjusting for patient-specific factors could reduce the VPC and MRR (i.e.
383 between-cluster variation) [23]. Second, the origin of infection was only a proxy for community-
384 acquired and hospital-acquired infection [24], and data of inter-hospital patient transfers were
385 not available in our study. A proportion of patients with community-origin BSI, therefore, could
386 be caused by nosocomial infections acquired at transferring hospitals. Third, mortality reported
387 in this study was all-cause in-hospital mortality, and could be much lower than the true all-cause
388 mortality because a preference to die at home is high in some regions in Thailand [25]. Fourth,
389 the difference in the percentage of patients having BC taken could be due to the differences in
390 case-mix. Further studies could additionally utilize antimicrobial prescription data to determine
391 proportion of patients having a BC taken within ± 1 calendar day of the day when a parenteral
392 antibiotic was started at the study hospital and continued for at least four consecutive days [21,
393 22]. This could improve our understanding of differences in diagnostic use practice between
394 hospitals and reinforce diagnostic stewardship activities in hospitals that underutilize BC among
395 sepsis patients.

396

397

398 **Conclusions**

399 Our findings highlight health regions where actions against community-acquired AMR infection,
400 including reduction of antibiotic overuse in the community, should be considered. Our findings
401 also highlight hospitals where actions against hospital-acquired AMR infection, including
402 antimicrobial stewardship, infection control and diagnostic stewardship, should be prioritized.

403 **Acknowledgements**

404 We gratefully acknowledge the laboratory team, IT team, antimicrobial stewardship team and
405 infection control team of all public referral hospitals in Thailand for their participation in the
406 activities of the Ministries of Public Health (MoPH), including utilization of the AMASS and
407 submission of summary data to the MoPH.

408

409 **Funding**

410 The study is supported by Ministry of Public Health Thailand and Wellcome Trust of Great
411 Britain (224681/Z/21/Z). For the purpose of Open Access, the author has applied a CC BY
412 public copyright licence to any Author Accepted Manuscript version arising from this
413 submission.

414

415 **Transparency declarations**

416 We declare that no competing interests exist.

417

418 **References**

- 419 1. WHO. Global Action Plan on Antimicrobial Resistance 2015. Available from:
420 <https://www.who.int/publications/i/item/9789241509763>.
- 421 2. WHO. WHO report on surveillance of antibiotic consumption. 2016-2018 early
422 implementation. 2019. Available from: [https://www.who.int/publications/i/item/who-report-on-](https://www.who.int/publications/i/item/who-report-on-surveillance-of-antibiotic-consumption)
423 [surveillance-of-antibiotic-consumption](https://www.who.int/publications/i/item/who-report-on-surveillance-of-antibiotic-consumption).
- 424 3. WHO. Global antimicrobial resistance and use surveillance systems | Country Profiles
425 [Available from: [https://www.who.int/data/gho/data/themes/topics/global-antimicrobial-](https://www.who.int/data/gho/data/themes/topics/global-antimicrobial-resistance-surveillance-system-glass/glass-country-profiles)
426 [resistance-surveillance-system-glass/glass-country-profiles](https://www.who.int/data/gho/data/themes/topics/global-antimicrobial-resistance-surveillance-system-glass/glass-country-profiles).
- 427 4. Johnson AP, Muller-Pebody B, Budd E, Ashiru-Oredope D, Ladenheim D, Hain D, et al.
428 Improving feedback of surveillance data on antimicrobial consumption, resistance and
429 stewardship in England: putting the data at your Fingertips. *J Antimicrob Chemother.*
430 2017;72(4):953-6.
- 431 5. Ashiru-Oredope D, Cunningham N, Casale E, Muller-Pebody B, Hope R, Brown CS, et
432 al. Reporting England's progress towards the ambitions in the UK action plan for antimicrobial
433 resistance: the English surveillance programme for antimicrobial utilisation and resistance
434 (ESPAUR). *J Antimicrob Chemother.* 2023;78(10):2387-91.
- 435 6. Walter J, Haller S, Blank HP, Eckmanns T, Abu Sin M, Hermes J. Incidence of invasive
436 meticillin-resistant *Staphylococcus aureus* infections in Germany, 2010 to 2014. *Euro Surveill.*
437 2015;20(46).
- 438 7. Lim C, Miliya T, Chansamouth V, Aung MT, Karkey A, Teparrukkul P, et al. Automating
439 the Generation of Antimicrobial Resistance Surveillance Reports: Proof-of-Concept Study
440 Involving Seven Hospitals in Seven Countries. *J Med Internet Res.* 2020;22(10):e19762.
- 441 8. Lim C, Hantrakun V, Klaytong P, Rangsiwutisak C, Tangwangvivat R, Phiancharoen C,
442 et al. Frequency and mortality rate following antimicrobial-resistant bloodstream infections in

- 443 tertiary-care hospitals compared with secondary-care hospitals. PLoS One.
444 2024;19(5):e0303132.
- 445 9. Srisuphan V, Klaytong P, Rangsiwutisak C, Tuamsuwan K, Boonyarit P,
446 Limmathurotsakul D. Local and timely antimicrobial resistance data for local and national
447 actions: the early implementation of an automated tool for data analysis at local hospital level in
448 Thailand. JAC Antimicrob Resist. 2023;5(4):dlad088.
- 449 10. Veerasarn K, Yuthagovit S, Chailorrrat A. Prevalence of Brain Tumor in Thailand from
450 2005 to 2014: Data from the National Health Security Office. J Med Assoc Thai. 2016;99 Suppl
451 3:S62-73.
- 452 11. Ministry of Public Health, Thailand. List of Healthcare Facilities under Health
453 Administration Division, Ministry of Public Health, Thailand 2023. 2023. Available from:
454 <http://dmsic.moph.go.th/index/detail/9188>.
- 455 12. Ministry of Public Health, Thailand. AMR Surveillance and Monitoring MoPH Dashboard
456 2023. Available from:
457 <https://app.powerbi.com/view?r=eyJrljoiZGY0ZTcxNmYmNlZi00ODAyLWEzYjctYzBhOGRIM2ZIN2YxliwidCI6IjM1YjAwOTJjLTM1MDYtNDliYS1iMWFjLTU0NmQwOTI1NzEyZCIsImMiOiEwfQ%3D%3D>.
- 459 <https://iris.who.int/bitstream/handle/10665/372741/9789240076600-eng.pdf>
- 460 13. WHO. GLASS manual for antimicrobial resistance surveillance in common bacteria
461 causing human infection. 2023. Available from:
462 <https://iris.who.int/bitstream/handle/10665/372741/9789240076600-eng.pdf>
- 463 14. Sinto R, Lie KC, Setiati S, Suwanto S, Nelwan EJ, Djumaryo DH, et al. Blood culture
464 utilization and epidemiology of antimicrobial-resistant bloodstream infections before and during
465 the COVID-19 pandemic in the Indonesian national referral hospital. Antimicrob Resist Infect
466 Control. 2022;11(1):73.

- 467 15. Teerawattanasook N, Tauran PM, Teparrukkul P, Wuthiekanun V, Dance DAB, Arif M, et
468 al. Capacity and Utilization of Blood Culture in Two Referral Hospitals in Indonesia and
469 Thailand. *Am J Trop Med Hyg.* 2017;97(4):1257-61.
- 470 16. National Statistical Office of Thailand. *Statistical Yearbook Thailand 2023*, 2023.
471 Available from: <https://www.nso.go.th/public/e-book/Statistical-Yearbook/SYB-2023>.
- 472 17. Austin PC, Stryhn H, Leckie G, Merlo J. Measures of clustering and heterogeneity in
473 multilevel Poisson regression analyses of rates/count data. *Stat Med.* 2018;37(4):572-89.
- 474 18. MacKinnon MC, McEwen SA, Pearl DL, Lyytikainen O, Jacobsson G, Collignon P, et al.
475 Increasing incidence and antimicrobial resistance in *Escherichia coli* bloodstream infections: a
476 multinational population-based cohort study. *Antimicrob Resist Infect Control.* 2021;10(1):131.
- 477 19. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD. Incidence, risk factors and
478 outcomes of *Escherichia coli* bloodstream infections in a large Canadian region. *Clin Microbiol*
479 *Infect.* 2008;14(11):1041-7.
- 480 20. Anugulruengkitt S, Charoenpong L, Kulthanmanusorn A, Thienthong V, Usayaporn S,
481 Kaewkhankhaeng W, et al. Point prevalence survey of antibiotic use among hospitalized
482 patients across 41 hospitals in Thailand. *JAC Antimicrob Resist.* 2023;5(1):dlac140.
- 483 21. Lim C, Hantrakun V, Teerawattanasook N, Srisamang P, Teparrukkul P, Sumpradit N, et
484 al. Impact of low blood culture usage on rates of antimicrobial resistance. *J Infect.*
485 2021;82(3):355-62.
- 486 22. Sinto R, Lie KC, Setiati S, Suwanto S, Nelwan EJ, Karyanti MR, et al. Diagnostic and
487 antibiotic use practices among COVID-19 and non-COVID-19 patients in the Indonesian
488 National Referral Hospital. *PLoS One.* 2024;19(3):e0297405.
- 489 23. Austin PC, Wagner P, Merlo J. The median hazard ratio: a useful measure of variance
490 and general contextual effects in multilevel survival analysis. *Stat Med.* 2017;36(6):928-38.

- 491 24. WHO. Global antimicrobial resistance surveillance system (GLASS) report: Early
492 implementation 2017-2018. 2019. Available from:
493 <https://apps.who.int/iris/bitstream/handle/10665/279656/9789241515061-eng.pdf?ua=1>.
494 25. Hongsuwan M, Srisamang P, Kanoksil M, Luangasanatip N, Jatapai A, Day NP, et al.
495 Increasing incidence of hospital-acquired and healthcare-associated bacteremia in northeast
496 Thailand: a multicenter surveillance study. PLoS One. 2014;9(10):e109324.
497

498 **Table 1. Characteristics of 111 public referral hospitals in Thailand, 2022**

Characteristics	Hospitals (N=111)
Total No. of bed size	54,564
Total No. of admissions	3,916,766
Total patient-days	23,675,466
Total No. of patients (de-duplicated)	3,042,979
Total No. of patients having BC taken (de-duplicated)*	618,187
Hospital characteristics	
Bed count, median (IQR)	421 (300-650)
No. of admissions, median (IQR)	27,847 (20,195-47,645)
Patient-days, median (IQR)	174,638 (115,129-287,015)
No. of patients, median (IQR)	22,399 (15,708-36,161)
No. of patients having BC taken, median (IQR) *	4,671 (2,768-7,222)
Percentage of patients having BC taken, median (IQR) **	20.0% (16.1-22.9%)
No. of patients having BC taken within the first two calendar days of hospital admission, median (IQR) ***	3,880 (2,405-6,336)
Percentage of patients having BC taken within the first two calendar days of hospital admission, median (IQR) ***	17.3% (13.1-20.2%)
No. of patients having the first BC taken after the first two calendar days of hospital admission, median (IQR) ***	815 (429-1,377)
Percentage of patients having the first BC taken after the first two calendar days of hospital admission, median (IQR) ***	3.4% (2.6-4.0%)
Rate of patients having BC taken per 1,000 patient-days, median (IQR)	26.4 (21.2-32.5)
Hospital level**	
Level A	35 (31.5%)
Level S	49 (24.3%)
Level M1	27 (44.1%)
Health regions	
1	10 (9.0%)
2	8 (7.2%)
3	5 (4.5%)
4	10 (9.0%)
5	15 (13.5%)
6	12 (10.8%)
7	6 (5.4%)
8	11 (9.9%)
9	7 (6.3%)
10	
11	12 (10.8%)
12	9 (8.1%)

499 BC=blood culture. *For total No. of patients having BC taken, the AMASS deduplicated the data by
 500 selecting only the first BC per patient per surveillance period. **Hospital level is defined by the MoPH
 501 Thailand. Level A is Advanced-level referral hospital, Level S is Standard-level referral hospital, and Level
 502 M1 is Mid-level referral hospital. ***Some patients had more than one admission, of which one had the
 503 first BC taken within the first two calendar days of hospital admission, and one had the first BC taken after
 504 the first two calendar days of admission.
 505
 506

507

508 **Table 2. Total No. of cases and deaths following AMR BSI in 111 public referral hospitals**
 509 **in Thailand, 2022**

AMR pathogens*	Total No. of patients	Total No. of in-hospital deaths	In-hospital mortality (%)
Community-origin BSI			
CRAB	664	343	51.7%
CRPA	300	67	22.3%
3GCREC	5,157	1,048	20.3%
3GCREC excluding CREC	4,758	953	20.0%
CREC	399	95	23.8%
3GCRKP	1,338	380	28.4%
3GCRKP excluding CRKP	860	222	25.8%
CRKP	478	158	33.1%
MRSA	370	98	26.5%
Total	7,829	1,936	24.7%
Hospital-origin BSI			
CRAB	4,926	2,955	60.0%
CRPA	484	241	49.8%
3GCREC	1,351	509	37.7%
3GCREC excluding CREC	1,072	381	35.5%
CREC	279	128	45.9%
3GCRKP	2,656	1,262	47.5%
3GCRKP excluding CRKP	1,078	428	39.7%
CRKP	1,578	834	52.9%
MRSA	185	69	37.3%
Total	9,602	5,036	52.4%

510
 511 BSI=bloodstream infection * Included carbapenem-resistant *Acinetobacter baumannii* (CRAB),
 512 carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), third-generation cephalosporin-resistant
 513 *Escherichia coli* (3GCREC) and *Klebsiella pneumoniae* (3GCRKP), carbapenem-resistant *E. coli* (CREC)
 514 and *K. pneumoniae* (CRKP), and methicillin-resistant *Staphylococcus aureus* (MRSA).
 515

516 **Table 3. Factors associated with the frequency of community-origin 3GCREC BSI per**
 517 **100,000 patients tested for community-origin BSI**

Factors	Crude incidence rate ratio (95% CI)	P value	Adjusted incidence rate ratio (95% CI)	P value
A	1.0	0.26	1.0	0.50
S	0.98 (0.82-1.17)		1.07 (0.84-1.36)	
M1	0.84 (0.68-1.05)		0.98 (0.71-1.33)	
Health regions				
1	1.33 (1.14-1.55)	<0.001	1.38 (1.03-1.85)	<0.001
2	1.77 (1.52-2.07)		1.90 (1.40-2.56)	
3	1.81 (1.53-2.15)		1.90 (1.35-2.67)	
4	1.94 (1.67-2.25)		2.07 (1.53-2.80)	
5	2.04 (1.78-2.35)		2.01 (1.52-2.65)	
6	1.94 (1.68-2.23)		1.92 (1.37-2.68)	
7	2.28 (1.97-2.62)		2.03 (1.47-2.80)	
8	1.71 (1.48-1.97)		1.67 (1.26-2.22)	
9	1.20 (1.04-1.40)		1.27 (0.92-1.75)	
10	1.23 (1.04-1.44)		1.24 (0.89-1.73)	
11	1.40 (1.20-1.62)		1.46 (1.10-1.94)	
12	1.0		1.0	
Hospital bed size (per 100 bed change)*	1.02 (0.99-1.05)	0.24	1.04 (0.99-1.09)	0.14
Gross provincial product*	1.08 (1.01-1.16)	0.034	0.99 (0.91-1.08)	0.83
Rate of patients having BC taken per 1,000 patient-days*	0.83 (0.77-0.90)	<0.001	-	-
Percentage of patients having BC taken within the first two calendar days of hospital admission (per 5 percentage point change)*	0.83 (0.77-0.90)	<0.001	0.88 (0.82-0.94)	<0.001

518
 519 * The rate ratios for the four continuous variables denote the relative change in the frequency of
 520 community-origin 3GCREC BSI per 100,000 patients with the first BC taken within the first 2 calendar
 521 days of hospital admissions (i.e. patients tested for community-origin BSI). All four continuous variables
 522 were standardized by centering at the mean values and divided by the standard deviation, except that
 523 hospital bed size was divided by 100 and the percentage of patients tested for community-origin BSI by 5.
 524 The multivariable model consists of 5,157 patients with community-origin 3GCREC BSI from 522,919
 525 patients tested for community-origin BSI from 111 hospitals.
 526

527

528

529 **Table 4. Factors associated with the frequency of hospital-origin CRAB BSI per 100,000**
 530 **patients tested for hospital-origin BSI**

Factors	Crude incidence rate ratio (95% CI)	P value	Adjusted incidence rate ratio (95% CI)	P value
Hospital levels				
A	1.0	<0.001	1.0	0.010
S	0.63 (0.49-0.79)		0.90 (0.62-1.32)	
M1	0.30 (0.22-0.41)		0.56 (0.34-0.93)	
Health regions				
1		0.40	1.33 (0.79-2.23)	0.096
2	1.58 (0.86-2.92)		2.11 (1.23-3.60)	
3	1.99 (1.00-3.97)		2.40 (1.31-4.38)	
4	1.49 (0.83-2.67)		1.99 (1.16-3.42)	
5	1.38 (0.81-2.36)		1.69 (1.03-2.78)	
6	1.83 (1.05-3.17)		1.93 (1.07-3.51)	
7	2.15 (1.10-4.17)		2.38 (1.35-4.20)	
8	1.26 (0.71-2.25)		1.57 (0.95-2.60)	
9	1.06 (0.56-2.03)			
10	1.11 (0.57-2.15)		1.18 (0.67-2.08)	
11	1.49 (0.85-2.61)		1.78 (1.07-2.98)	
12	1.54 (0.86-2.79)		1.76 (1.05-2.96)	
Hospital bed size (per 100 bed change)*	1.16 (1.11-1.21)	<0.001	1.15 (1.06-1.24)	0.001
Gross provincial product*	1.10 (0.98-1.23)	0.12	1.03 (0.90-1.17)	0.62
Rate of patients having BC taken per 1,000 patient-days*	0.99 (0.86-1.12)	0.83		-
Percentage of patients having BC taken after the first two calendar days of hospital admission (per 1 percentage point change)*	1.16 (1.05-1.27)	0.002	0.91 (0.82-1.00)	0.060

531
 532 * The rate ratios for the four continuous variables denote the relative change in the frequency of hospital-
 533 origin CRAB BSI per 100,000 patients with the first BC taken after the first 2 calendar days of hospital
 534 admissions (i.e. patients tested for hospital-origin BSI). All four continuous variables were standardized by
 535 centering at the mean values and divided by the standard deviation, except that hospital bed size was
 536 divided by 100 and the percentage of patients tested for hospital-origin BSI by 1. The multivariable model
 537 consists of 4,926 patients with hospital-origin CRAB BSI from 115,516 patients tested for hospital-origin
 538 BSI from 111 hospitals.
 539

540 **Figure legends**

541

542 **Figure 1. Health regions in Thailand (1A) and expected frequency of community-origin**
543 **3GCREC BSI (1B) by health regions**

544 Footnote of figure 1. For each health region, the expected frequency was estimated based on
545 the total number of expected cases per the total number of patients tested for BSI in the
546 provinces. The number of expected cases was calculated using the fixed effects of the
547 covariates in the final model and assuming that all hospitals had the percentage of patients
548 having BC taken within the first 2 days of hospital admission at the mean value (16.9%).



549

550

551 **Figure 2. New interactive Thailand AMR dashboard [12]**

552 Footnote of figure 2. Thai words were translated to English and highlighted in green color. The
553 picture was captured from the website [12] on 30 June 2023.

554

A**B**

Health region

- Select all
- (01)
- (02)
- (03)
- (04)
- (05)
- (06)
- (07)
- (08)
- (09)
- (10)
- (11)
- (12)
- (13)

Region

- Select all
- North
- South
- Central
- West
- East
- Northeast


Hospital level

- Select all
- [A]
- [M1]
- [S]

Year (months)

- 2021
- 6
- 12
- 2022
- 6
- 12
- 2023
- 6
- 12
- 2024

AMR surveillance: Service Plan MOPH (Bloodstream infection and death involving AMR)



Indicators


- AMR_CASE
- AMR_DEATH
- %AMR_CASE
- %AMR_DEATH

Infection of origin

- Select all
- Community-origin
- Hospital-origin

Organism

- Select all
- Acinetobacter baumannii
- Enterococcus spp.
- Escherichia coli
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
- Salmonella spp.
- Staphylococcus aureus
- Streptococcus pneumoniae



Community-origin and Hospital-origin								
Health region	Number_of_BSI	AMR_CASE	AMR_DEATH	%AMR_CASE	%AMR_DEATH			
(01)	4,242	1,369	520	1369/4242 (32.27%)	32.27%	520/1369 (37.98%)	37.98%	
(02)	3,441	1,264	593	1264/3441 (36.73%)	36.73%	593/1264 (46.91%)	46.91%	
(03)	2,681	1,075	494	1075/2681 (40.10%)	40.10%	494/1075 (45.95%)	45.95%	
(04)	3,874	1,402	689	1402/3874 (36.19%)	36.19%	689/1402 (49.14%)	49.14%	
(05)	5,561	1,978	848	1978/5561 (35.57%)	35.57%	848/1978 (42.87%)	42.87%	
(06)	5,699	2,224	1,020	2224/5699 (39.02%)	39.02%	1020/2224 (45.86%)	45.86%	
(07)	4,530	2,155	624	2155/4530 (47.57%)	47.57%	624/2155 (28.96%)	28.96%	
(08)	4,529	1,647	466	1647/4529 (36.37%)	36.37%	466/1647 (28.29%)	28.29%	
(09)	4,447	1,673	666	1673/4447 (37.62%)	37.62%	666/1673 (39.81%)	39.81%	
(10)	3,909	1,746	629	1746/3909 (44.67%)	44.67%	629/1746 (36.03%)	36.03%	
(11)	4,275	1,500	571	1500/4275 (35.09%)	35.09%	571/1500 (38.07%)	38.07%	
(12)	3,707	1,206	403	1206/3707 (32.53%)	32.53%	403/1206 (33.42%)	33.42%	
Total	50,895	19,239	7,523	19239/50895 (37.80%)	37.80%	7523/19239 (39.10%)	39.10%	

Community-origin and Hospital-origin								
Organism	Number_of_BSI	AMR_CASE	AMR_DEATH	%AMR_CASE	%AMR_DEATH			
Acinetobacter baumannii	7636	5,775	3,424	5775/7636 (75.63%)	75.63%	3424/5775 (59.29%)	59.29%	
Enterococcus spp.	3698	248	126	248/3698 (6.71%)	6.71%	126/248 (50.81%)	50.81%	
Escherichia coli	17937	6,845	1,630	6845/17937 (38.16%)	38.16%	1630/6845 (23.81%)	23.81%	
Klebsiella pneumoniae	9956	4,298	1,731	4298/9956 (43.17%)	43.17%	1731/4298 (40.27%)	40.27%	
Pseudomonas aeruginosa	2812	798	309	798/2812 (28.38%)	28.38%	309/798 (38.72%)	38.72%	
Salmonella spp.	1381	666	124	666/1381 (48.23%)	48.23%	124/666 (18.62%)	18.62%	
Staphylococcus aureus	6888	569	167	569/6888 (8.26%)	8.26%	167/569 (29.35%)	29.35%	
Streptococcus pneumoni...	587	40	12	40/587 (6.81%)	6.81%	12/40 (30.00%)	30.00%	
Total	50895	19,239	7,523	19239/50895 (37.80%)	37.80%	7523/19239 (39.10%)	39.10%	